REG - Oxford BioDynamics - OBD partners with Goodbody Clinic on PSE test

Oxford BiodynamicsAnnouncement

23/05/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240523:nRSW5484Pa&default-theme=true

RNS Number : 5484P  Oxford BioDynamics PLC  23 May 2024

Oxford BioDynamics
("OBD" or the "Company" and, together with its subsidiaries, the "Group")

 

Oxford BioDynamics partners with Goodbody Clinic to offer

nationwide access to the EpiSwitch® PSE test

 

·    Goodbody Clinic
(https://health.goodbodyclinic.com/product/episwitch-pse-advanced-blood-test/)
to offer the EpiSwitch® Prostate Screening Test (PSE) at all its locations
across the UK, supported by its network of GPs

·    Expands access to EpiSwitch® PSE simplifying both the test
requisitioning and sample collection

·    Goodbody Clinic is a provider of private health tests using a network
of over 140 clinics

·    Goodbody Clinic will also offer men the option of booking a nurse
visit to come to their home for blood collection

Oxford, UK - 23 May 2024 - Oxford BioDynamics Plc (AIM: OBD, the "Company"), a
biotechnology company developing precision medicine tests based on the
EpiSwitch® 3D genomics platform, and the Goodbody Clinic, a nationwide
provider of private health testing services, have signed an agreement to give
Goodbody Clinic patients access to OBD's EpiSwitch PSE (EpiSwitch Prostate
Screening) blood test.

OBD's EpiSwitch PSE test is a blood test that boosts the predictive accuracy
of a standard PSA test from 55% to 94% when testing for the presence or
absence of prostate cancer, which was launched in the UK and US in September
2023 (see www.94percent.com (https://www.94percent.com/) ).

The Goodbody Clinic offers customers private health testing using a network of
over 140 clinics nationwide. By partnering with OBD, the Goodbody Clinic will
immediately offer the EpiSwitch PSE test at all its locations across the UK.
Using the Goodbody Clinic website, men can request to order a PSE test from
one of the clinics' registered GPs, pay for their test, and book an
appointment for their blood sample to be taken at their local clinic. The
Goodbody Clinic will also provide a remote doctor's referral and consultation
to support patients to ensure they receive the appropriate care.

For those unable to come into one of the Goodbody clinics, men will have the
option of having their PSE blood sample drawn at any location by booking a
mobile nurse visit. The Goodbody Clinic operates a growing network of mobile
phlebotomists across the UK, operating from Scotland down to Cornwall.

George Thomas, Chief Executive Officer of Goodbody Clinic, said: "The rapid
EpiSwitch PSE test can significantly enhance the accuracy of detecting
prostate cancer, allowing us to provide better care and peace of mind to men
throughout the whole country. We are always looking to advance our commitment
to accessible, high-quality healthcare by combining the latest innovations
like the PSE with access to Goodbody's convenient clinics and home testing
solutions."

To order the PSE test from the Goodbody Clinic, visit:
https://health.goodbodyclinic.com/product/episwitch-pse-advanced-blood-test/
(https://health.goodbodyclinic.com/product/episwitch-pse-advanced-blood-test/)

Thomas Guiel, Chief Operating Officer of Oxford BioDynamics, said: "This
agreement presents an important new point of patient access for the EpiSwitch
PSE test, allowing us to further extend the availability and reach of our
highly accurate prostate cancer test."

The PSE test is the culmination of nearly ten years of collaborative work
between OBD, Imperial College London, the University of East Anglia, Imperial
College NHS Trust, and leading UK prostate cancer experts, as part of the
PROSTAGRAM screening pilot. As well as a high 94% accuracy, PSE offers high
specificity, 97% (standard PSA alone: 53%), and high sensitivity, 86% (PSA:
64%), as well as high positive, 93% (PSA: 25%(1)), and high negative, 95%
(PSA: 86%(1)) predictive values to assess the risk of prostate cancer in men,
published in the peer-reviewed publication, Cancers(2).

References

1.        NHS Health A to Z. Prostate cancer: PSA testing (2021).
https://www.nhs.uk/conditions/prostate-cancer/psa-testing
(https://www.nhs.uk/conditions/prostate-cancer/psa-testing)

2.        Pchejetski D, Hunter E, Dezfouli M, et al. (2023).
Circulating Chromosome Conformation Signatures Significantly Enhance PSA
Positive Predicting Value and Overall Accuracy for Prostate Cancer Detection.
Cancers. 2023; 15(3):821. https://doi.org/10.3390/cancers15030821
(https://doi.org/10.3390/cancers15030821)

- Ends -

 

 For further details please contact:

 Oxford BioDynamics Plc                                             +44 (0)1865 518910

 Jon Burrows, CEO

 Paul Stockdale, CFO

 Shore Capital                                                      +44 (0)20 7408 4090

(Nominated Adviser and Broker to OBD)

 Stephane Auton

 Lucy Bowden

 WG Partners                                                        +44 (0)20 3705 9330

 (Joint Broker to OBD)

 David Wilson / Claes Spång / Sateesh Nadarajah / Erland Sternby

 Instinctif Partners                                                Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com
 (Media / Analyst enquiries for OBD)

Melanie Toyne-Sewell / Katie Duffell / Jack Kincade

 Goodbody Clinic                                                    Tel: +44 (0)1373 486650

 George Thomas

 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing
personalized healthcare by developing and commercializing precision medicine
tests for life-changing diseases.

Its flagship products are the EpiSwitch® CiRT
(https://url.avanan.click/v2/___https:/www.mycirt.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjphN2EwOmU5ZDc2NmYxZjYxNTk4OGE3YzY3NzkzYWRmODlmMmZmMzBmZmU2ZDZlZmNhMWI0ZmRlYjE3Nzc5N2Q4NmUzZTc6cDpU)
(Checkpoint Inhibitor Response Test) and EpiSwitch® PSE
(https://url.avanan.click/v2/___http:/www.94percent.com/___.YXAxZTpzaG9yZWNhcDphOm86NDM3OWRhZTU0OTFmMzEyYzg3YTA3NTlmNzczMzUyYTY6NjplNjRjOjkyNjc0OWI0ZDVjYmU1OWRkNmM4YTg4NzgyZDc4MDM1OWM0YzA0MzcxYjZjYzYzYzY0YmZhYWUzYTAzYzJjYjM6cDpU)
(EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune
response profile for immuno-oncology (IO) checkpoint inhibitor treatments,
launched in February 2022. PSE is a blood test that boosts the predictive
accuracy of a PSA test from 55% to 94% when testing the presence or absence of
prostate cancer, which was launched in the US and UK in September 2023.

In March 2021, the Company launched its first commercial prognostic test,
EpiSwitch® CST
(https://url.avanan.click/v2/___https:/covidseveritytest.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpmZWY1OmMzOGIyYTk2Yjk1OTgyMDNlMGFkNmQwZGU3ZmNmYzQwMzZmMGIwZDQ5NzA0OTAzNDc0NzY2ZDQyZGZiYjk5YWU6cDpU)
(Covid Severity Test) and the first commercially available microarray kit for
high-resolution 3D genome profiling and biomarker discovery, EpiSwitch®
Explorer Array Kit
(https://url.avanan.click/v2/___https:/store.oxfordbiodynamics.com/___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjpiMWU2OjMzMTc0NWQ5ZWZhODg0MmY1N2EzZjY2YWRkZDI5YjBkOTRhM2M0ZTZkOGJkNWM2Y2I5MDE4MmQ4M2Y4ZjViMDY6cDpU)
, which is available for purchase by the life science research community.

The Company's product portfolio is based on a proprietary 3D genomic biomarker
platform, EpiSwitch®, which can build molecular diagnostic classifiers for
the prediction of response to therapy, patient prognosis, disease diagnosis
and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big
pharma and leading institutions including Pfizer, EMD Serono, Genentech,
Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi
Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker
arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an
expertly curated 3D genome knowledgebase comprising hundreds of millions of
data points from over 15,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock
Exchange. It also has a commercial office in Gaithersburg and a clinical
laboratory in Frederick, MD, USA, and a reference laboratory in Penang,
Malaysia.

For more information, please visit the Company's website,
www.oxfordbiodynamics.com
(https://url.avanan.click/v2/___http:/www.oxfordbiodynamics.com___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo3ZjFmOjUxZjRiNmRmMzBiMGI3ZjA2NDJjNjFkZTc2MTM5MThjYjUxZGNiN2ZhNmRhNWRkMjY0MTAwNWY4ODA3ZjE4ZjU6cDpU)
, or follow OBD on Twitter
(https://url.avanan.click/v2/___https:/twitter.com/OxBioDynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6NjplM2FmOjIwMTI1ZWNlOWJkYjRjZDQ1YjA4YWI2NDc0NWY1OWYzNzg1NTEzYjM0NjIwYTZmNTljNjk0YTQ1YzBkMjg0OTM6cDpU)
(@OxBioDynamics) and LinkedIn
(https://url.avanan.click/v2/___https:/www.linkedin.com/company/oxford-biodynamics___.YXAxZTpzaG9yZWNhcDphOm86OTRjOGE5ZDRmYWIwMTc2MWFhZjYyZTZkMWJhZTFmNDg6Njo2YjgzOjcwMGI3YTM5ODdkMDVmNjA5ZDgxN2FmYWVjYTJkMjIzM2E3NTgzYzM0ZGIzMGIyZDIyYWZlZTVjN2QyZmY4ZGQ6cDpU)
.

 

About Goodbody Wellness Limited

Goodbody Wellness Limited is an aggregator of the highest quality, most
innovative range of health and wellness services and products using the latest
technology. With over 80 products today, tests include blood, genetic, cancer
and other diagnostic solutions to meet today's fast evolving consumer
expectations with more than 250,000 tests completed to date.

 

About EpiSwitch®

The 3D configuration of the genome plays a crucial role in gene regulation. By
mapping this architecture and identifying abnormal configurations, EpiSwitch®
can be used to diagnose patients or determine how individuals might respond to
a disease or treatment.

Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics'
award-winning, proprietary platform that enables screening, evaluation,
validation and monitoring of 3D genomic biomarkers. The technology is fully
developed, based on testing of over 15,000 samples in 30 disease areas, and
reduced to practice.

In addition to stratifying patients with respect to anticipated clinical
outcomes, EpiSwitch® data offer insights into systems biology and the
physiological manifestation of disease that are beyond the scope of other
molecular modalities. The technology has performed well in academic medical
research settings and has been validated through its integration in biomarker
discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRSEUFAEELSEEI